Fintel reports that on October 20, 2025, Guggenheim maintained coverage of AbbVie (NYSE:ABBV) with a Buy recommendation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback